#United States #St. Louis #biotechnology #Panome Bio #Jean-Pierre Wery

Panome Bio Welcomes a New Visionary to Its Board

Panome Bio, a pioneering company specializing in discovery services, is pleased to announce the latest addition to its Board of Directors: Jean-Pierre Wery, an esteemed leader in the biotechnology sector. This strategic appointment comes at a crucial time as Panome Bio prepares for significant expansion in 2025 to accommodate the growing demands of the biopharmaceutical industry.

Founded in 2022, Panome Bio has quickly established itself as a major player in the field of life sciences, leveraging advanced methodologies such as metabolomics and proteomics. The company's comprehensive abilities focus on data analytics and multi-omic integration, enabling researchers and clients to delve deeper into biological systems, uncover new insights, and optimize their discovery processes. With such a strong foundation already in place, the expertise brought by Dr. Wery is expected to propel the company into its next growth phase.

"We are excited to welcome Dr. Wery to our Board of Directors, reinforcing our commitment to innovation and excellence in the scientific community," commented Edward Weinstein, CEO, and Co-founder of Panome Bio. Dr. Wery, known for his extensive background in scaling life sciences companies, holds a track record of success that includes his most recent tenure as CEO of Crown Bioscience, where he oversaw impressive revenue growth exceeding $100 million annually.

Expressing his enthusiasm, Dr. Wery stated, "Panome Bio is poised at the cutting edge of a transformational shift in drug development and discovery. I'm thrilled to join the Board and look forward to driving the adoption of multi-omic methodologies that can revolutionize research capabilities in this field."

Panome Bio's recent growth and service diversification, which includes a new suite of metabolomic tools designed to analyze the microbiome effectively, reflects its proactive approach in staying ahead of industry trends and customer needs. The strategic partnership with Telegraph Hill Partners, which has also been instrumental in enabling further financing and partnership opportunities, underscores the promising future ahead for Panome Bio.

Furthermore, the synergy within the Board is bolstered by additional members such as Deval Lashkari and Rob Capone from Telegraph Hill Partners, alongside other experienced leaders, which positions Panome Bio strongly within the scientific community. Deval Lashkari remarked, "JP's appointment significantly strengthens our Board. His wisdom and vision will provide the required guidance as we push the frontiers of discovery science forward."

In summary, as Panome Bio gears up for a transformative 2025, the combination of high-caliber leadership and innovative scientific initiatives underlines the determination to contribute to the evolution of biopharmaceutical research. By harnessing the capabilities of multi-omics and continuing to foster collaborative partnerships, Panome Bio is not just anticipating growth; it is actively shaping the future of life sciences.

For further information about Panome Bio and its services, you can visit their official website or connect with them on LinkedIn.